TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07315113: Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Sponsor: Nuvectis Pharma, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT07315113 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07315113 Rescue Dossier →